Mechanisms of action and targets for actual and future antiplatelet drugs.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Mini-Reviews in Medical Chemistry

• Publication date

  2006-05-31

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2174/138955706777435661PMID 16787383
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protease‐activated receptors in hemostasis, thrombosis and vascular biology

  2005cited by this paper
• Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.

  2005cited by this paper
• Role of CD39 (NTPDase-1) in Thromboregulation, Cerebroprotection, and Cardioprotection

  2005cited by this paper
• The pituitary adenylate cyclase-activating polypeptide is a physiological inhibitor of platelet activation.

  2004cited by this paper
• Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events

  2002cited by this paper
• Structure and stereochemistry of the active metabolite of clopidogrel.

  2002cited by this paper
• Update on aspirin in the treatment and prevention of cardiovascular disease.

  2002cited by this paper
• Involvement of Glycoprotein VI in Platelet Thrombus Formation on Both Collagen and von Willebrand Factor Surfaces Under Flow Conditions

  2002cited by this paper
• Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study

  2002cited by this paper
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

  2002cited by this paper
• Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study.

  2002cited by this paper
• Platelet Glycoprotein IIb/IIIa Inhibitors: Recognition of a Two-Edged Sword?

  2002cited by this paper
• Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.

  2002cited by this paper
• Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.

  2001cited by this paper
• Long-Term Antithrombotic Protection by in Vivo Depletion of Platelet Glycoprotein VI in Mice

  2001cited by this paper
• Circulating Monocyte-Platelet Aggregates Are a More Sensitive Marker of In Vivo Platelet Activation Than Platelet Surface P-Selectin: Studies in Baboons, Human Coronary Intervention, and Human Acute Myocardial Infarction

  2001cited by this paper
• Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.

  2001cited by this paper
• Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.

  2001cited by this paper
• Profile and prevalence of aspirin resistance in patients with cardiovascular disease.

  2001cited by this paper
• Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

  2001cited by this paper
• ADP Receptors of Platelets and their Inhibition

  2001cited by this paper
• Anti-Human von Willebrand Factor Monoclonal Antibody AJvW-2 Prevents Thrombus Deposition and Neointima Formation After Balloon Injury in Guinea Pigs

  2000cited by this paper
• Cyclooxygenases: structural, cellular, and molecular biology.

  2000cited by this paper
• A revised model of platelet aggregation.

  2000cited by this paper
• Identification and Biological Activity of the Active Metabolite of Clopidogrel

  2000cited by this paper
• Thrombotic thrombocytopenic purpura associated with clopidogrel.

  2000cited by this paper
• Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions.

  2000cited by this paper
• Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates.

  2000cited by this paper
• Structural basis of collagen recognition by integrin alpha2beta1.

  2000cited by this paper
• In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist.

  1999cited by this paper
• Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.

  1999cited by this paper
• Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation

  1999cited by this paper
• Collagen Receptor Signaling in Platelets and Megakaryocytes

  1999cited by this paper
• Ticlopidine and clopidogrel.

  1999cited by this paper
• Molecular identification of the cross-reacting epitope on alphaM beta2 integrin I domain recognized by anti-alphaIIb beta3 monoclonal antibody 7E3 and its involvement in leukocyte adherence.

  1998cited by this paper
• Recombinant von Willebrand factor fragment AR545C inhibits platelet aggregation and enhances thrombolysis with rtPA in a rabbit thrombosis model.

  1998cited by this paper
• Identification of a novel calcium-binding protein that interacts with the integrin alphaIIb cytoplasmic domain.

  1997cited by this paper
• The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39.

  1997cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

  1996cited by this paper
• Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically.

  1995cited by this paper
• The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase

  1995cited by this paper
• An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey.

  1995cited by this paper
• Platelet Activation: Signal Transduction Via Membrane Receptors

  1995cited by this paper
• Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383.

  1995cited by this paper
• Antithrombotic Effect of a Recombinant von Willebrand Factor, VCL, on Nitrogen Laser-Induced Thrombus Formation in Guinea Pig Mesenteric Arteries

  1995cited by this paper
• Abolition of Cyclic Flow Variations in Stenosed, Endothelium‐Injured Coronary Arteries in Nonhuman Primates With a Peptide Fragment (VCL) Derived From Human Plasma von Willebrand Factor–Glycoprotein Ib Binding Domain

  1994cited by this paper
• The Antiaggregating Activity of Clopidogrel Is due to a Metabolic Activation by the Hepatic Cytochrome P450-1A

  1994cited by this paper
• Aspirin does not inhibit adenosine diphosphate-induced platelet alpha-granule release.

  1993cited by this paper
• Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients.

  1993cited by this paper
• Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa.

  1993cited by this paper
• Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits.

  1993cited by this paper
• The Effect of Thrombin Inhibitors on Tissue Plasminogen Activator Induced Thrombolysis in a Rat Model

  1992cited by this paper
• A monomeric von Willebrand factor fragment, Leu-504--Lys-728, inhibits von Willebrand factor interaction with glycoprotein Ib-IX [corrected].

  1992cited by this paper
• Structure of the human pituitary adenylate cyclase activating polypeptide (PACAP) gene.

  1992cited by this paper
• Selective recognition of adhesive sites in surface-bound fibrinogen by glycoprotein IIb-IIIa on nonactivated platelets.

  1991cited by this paper
• Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris.

  1990cited by this paper
• Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group.

  1990cited by this paper
• A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group.

  1989cited by this paper
• The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke.

  1989cited by this paper
• Platelet activation in unstable coronary disease.

  1986cited by this paper
• The effect of 5-(2-chlorobenzyl)-5,6,7,7a-tetrahydro 4H-thieno (3.2-C)-pyridine-2-one hydrochloride (PCR 3787), a metabolite of ticlopidine, on the aggregation of human platelets in vitro and on the aggregation inhibiting action of PGI2 and PGD2.

  1984cited by this paper
• Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase.

  1984cited by this paper
• Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study.

  1983cited by this paper
• Ibuprofen Protects Platelet Cyclooxygenase from Irreversible Inhibition by Aspirin

  1983cited by this paper
• [Ticlopidine in heart surgery with cardiopulmonary by-pass (author's transl)].

  1980cited by this paper
• Inhibition of platelet prostaglandin synthetase by oral aspirin.

  1978cited by this paper
• The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein.

  1975cited by this paper

• The role of resistance to acetylsalicylic acid in patients with ischemic stroke

  2019cites this paper
• New urushiols with platelet aggregation inhibitory activities from resin of Toxicodendron vernicifluum.

  2016cites this paper
• DGRh-Empfehlungen zur Implementierung aktueller Sicherheitsaspekte in die NSAR- Therapie muskuloskelettaler Schmerzen

  2016cites this paper
• DGRh-Empfehlungen zur Implementierung aktueller Sicherheitsaspekte in die NSAR-Therapie muskuloskelettaler Schmerzen

  2016cites this paper
• Design, Virtual Screening, and Synthesis of Antagonists of αIIbβ3 as Antiplatelet Agents.

  2015cites this paper
• Consensus Drug Design Using IT Microcosm

  2014cites this paper
• Effects of extraction condition on structural features and anticoagulant activity of F. vesca L. conjugates.

  2013cites this paper
• OCENA OPORNO ŚCI NA SKOJARZONE LECZENIE PRZECIWPËYTKOWE U CHORYCH Z TROPONINODODATNIM OSTRYM ZESPOËEM WIE ŃCOWYM LECZONYCH INWAZYJNIE

  2013cites this paper
• Synthesis, biological evaluation, X-ray molecular structure and molecular docking studies of RGD mimetics containing 6-amino-2,3-dihydroisoindolin-1-one fragment as ligands of integrin αIIbβ₃.

  2013cites this paper
• Splitomicin suppresses human platelet aggregation via inhibition of cyclic AMP phosphodiesterase and intracellular Ca++ release.

  2009cites this paper
• New antiplatelet therapies for acute coronary syndromes

  2007cites this paper